AOD-9604 Peptide Dosing Chart: Research Amounts, Timing, and Safety

AOD-9604 peptide dosing chart: typical research amounts, timing, injection tips, and safety notes, plus how it compares with other fat-loss compounds.

ARTICLE OVERVIEW

AOD-9604 peptide dosing chart: typical research amounts, timing, injection tips, and safety notes, plus how it compares with other fat-loss compounds.

AOD-9604 is most often researched at 250–500 mcg per day, given as a single subcutaneous injection, usually in a fasted state. That range comes from early human trials and community logs rather than an official prescribing guideline. AOD-9604 is not FDA-approved for human use in the United States, so any AOD-9604 peptide dosing chart summarizes research practice, not medical advice.

What AOD-9604 Is and What the Research Suggests

AOD-9604 is a synthetic peptide fragment of human growth hormone, covering amino acids 176–191 of the HGH chain. Scientists designed that fragment to target fat metabolism while avoiding the blood sugar spikes and broad growth signaling linked to full HGH.

Early studies looked at obesity and fat reduction, but the trials were small and the results were mixed. Reported peptide aod 9604 benefits include support for fat loss and a neutral effect on blood glucose in some studies, yet no large trial has confirmed a dependable clinical benefit.

  • Mechanism: mimics part of HGH's fat-mobilizing activity.
  • Hormone impact: does not appear to raise IGF-1 the way full HGH does.
  • Status: research chemical, not an approved medication.

AOD-9604 Peptide Dosing Chart

The table below collects the daily amounts most often cited in research summaries and user reports. Individual responses vary, and no dose is officially established for humans.

Dose LevelTypical Daily AmountFrequencyNotes
Low250 mcgOnce dailyOften used as a starting point.
Standard300 mcgOnce dailyMost frequently mentioned amount.
Moderate400–500 mcgOnce dailyUpper end of the commonly reported range.
Split250 mcg twice dailyTwice dailySome users split for steadier levels; less studied.

Amounts above 500 mcg per day are not well documented in human research, so they carry more uncertainty. A clinician familiar with peptide therapies can help interpret what a given amount might mean in a specific situation.

AOD 9604 Dosing Protocol: Timing and Injection Basics

A typical aod 9604 dosing protocol keeps the routine simple and repeatable, though none of it is backed by formal prescribing guidance.

  1. Timing: inject in the morning on an empty stomach, roughly 30 minutes before the first meal.
  2. Site: subcutaneous fat on the abdomen, rotating spots to reduce irritation.
  3. Equipment: a 28–31 gauge insulin syringe is typical for the small volumes involved.
  4. Cycle: 8–12 weeks on, followed by a break, is a common pattern.

Knowing when to take aod 9604 peptide matters because food may affect absorption in some users' experience, although this has not been firmly established in trials. Some people prefer an evening dose, and consistency matters more than the exact clock time.

AOD 9604 Peptide vs Tesamorelin

These two compounds are often compared because both target fat, but they work in different ways and sit in different regulatory categories.

FeatureAOD-9604Tesamorelin
TypeHGH fragment (176–191)Growth hormone–releasing hormone analog
FDA statusNot approved for human useFDA-approved for HIV-associated lipodystrophy
Typical dose250–500 mcg daily1–2 mg daily
IGF-1 effectMinimal in reported dataRaises IGF-1
Common goalFat metabolism supportVisceral fat reduction

The comparison matters because tesamorelin comes with prescription oversight, a defined dose, and monitoring requirements, while AOD-9604 does not. Any discussion of aod 9604 peptide vs tesamorelin should account for that gap in regulation and safety data.

AOD 9604 Peptide Capsules and Other Forms

Oral products are widely sold, but aod 9604 peptide capsules face a basic problem: peptides are usually broken down during digestion. That makes swallowing the compound a poor substitute for injection in most researchers' view.

  • Injections: the form used in studies and most user reports.
  • Capsules: convenient, but likely low bioavailability.
  • Nasal sprays and creams: limited evidence for meaningful absorption.

If oral use is the only option someone will consider, the practical amount may need to be much higher — and even then, results are unpredictable. Anyone comparing vendors should look for third-party lab testing, since purity varies widely.

AOD-9604 is not FDA-approved for human use in the United States, and it is typically sold as a research chemical. That means no regulated dose, no pharmacy oversight, and no guaranteed purity.

Reported side effects in user accounts are generally mild and include injection site reactions, headache, and fatigue. Because long-term human data are limited, the full risk profile remains unknown.

People with hormone-sensitive conditions, pregnant or breastfeeding individuals, and anyone taking prescription medication should talk with a healthcare professional before using any research peptide. A dosing chart cannot replace individualized medical advice.

Frequently Asked Questions

What is the typical AOD-9604 peptide dose per day?

Most research summaries and user reports cite 250–500 mcg per day, with 300 mcg as the most commonly mentioned amount. It is usually given as one subcutaneous injection. No official human dose has been established because AOD-9604 is not an approved medication.

When should I take AOD-9604 peptide?

Most protocols place the injection in the morning on an empty stomach, about 30 minutes before eating. Some users split the amount into two smaller doses or move it to the evening. Consistency in timing appears to matter more than the exact hour.

Is AOD-9604 FDA-approved or legal to buy?

AOD-9604 is not FDA-approved for human use in the United States and is generally sold as a research chemical. Legal status can vary by state and by how the product is marketed. Purity is not guaranteed, so third-party lab testing is important if someone chooses to purchase it.

Research information notice

This page provides educational research information and does not replace medical advice, diagnosis, or treatment.